Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Aisha S. Sie"'
Autor:
L. Derks, A. van Erkelens, Nicoline Hoogerbrugge, Judith B. Prins, G.H. Woldringh, Aisha S. Sie, L. Egbers, Peggy Manders
Publikováno v:
Journal of Genetic Counseling, 26, 4, pp. 785-791
Journal of Genetic Counseling, 26, 785-791
Europe PubMed Central
Journal of Genetic Counseling
Journal of Genetic Counseling, 26, 785-791
Europe PubMed Central
Journal of Genetic Counseling
Contains fulltext : 177380.pdf (Publisher’s version ) (Open Access) BRCA1/2-mutation carriers are at high risk of breast cancer (BC) and ovarian cancer. Physical inactivity, overweight (body mass index >/=25, BMI), smoking, and alcohol consumption
Autor:
A. van Erkelens, M. B. W. Spanier, Judith B. Prins, Aisha S. Sie, A. Visser, M. C. A. van Kouwen, Nicoline Hoogerbrugge
Publikováno v:
Colorectal Disease, 20, 897-904
Colorectal Disease, 20, 10, pp. 897-904
Colorectal Disease, 20, 10, pp. 897-904
AIM Most people who are at increased familial colorectal cancer (FCRC) risk are not identified, despite the need for enhanced surveillance colonoscopy for effective CRC prevention. An online self-test may enhance this identification. We assessed whet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49c71bf6da367876ba23302588781273
http://hdl.handle.net/2066/196645
http://hdl.handle.net/2066/196645
Autor:
Judith B. Prins, Arjen R. Mensenkamp, Han G. Brunner, Liesbeth Spruijt, Wendy A. G. van Zelst-Stams, Aisha S. Sie, Marjolijn J. L. Ligtenberg, Nicoline Hoogerbrugge
Publikováno v:
Journal of Genetic Counseling, 25, 3, pp. 504-14
Journal of Genetic Counseling, 25, 504-14
Journal of Genetic Counseling
Journal of Genetic Counseling, 25, 504-14
Journal of Genetic Counseling
Contains fulltext : 167845.pdf (Publisher’s version ) (Open Access) According to standard practice following referral to clinical genetics, most high risk breast cancer (BC) patients in many countries receive face-to-face genetic counseling prior t
Autor:
Marcel R. Nelen, Aisha S. Sie, Michiel Simons, Marjolijn J. L. Ligtenberg, Encarna B. Gomez-Garcia, Johan Bulten, Alexander Hoischen, Hicham Ouchene, Marinus J. Blok, Nicoline Hoogerbrugge, Arjen R. Mensenkamp, Joanne A. de Hullu, Bastiaan B J Tops, Monique van Asseldonk, Robbert D.A. Weren, Astrid Eijkelenboom
Publikováno v:
Human Mutation, 38(2), 226-235. Wiley
Human Mutation, 38, 226-235
Human Mutation
Human Mutation, 38, 2, pp. 226-235
Human Mutation, 38, 226-235
Human Mutation
Human Mutation, 38, 2, pp. 226-235
With the recent introduction of Poly(ADP‐ribose) polymerase inhibitors, a promising novel therapy has become available for ovarian carcinoma (OC) patients with inactivating BRCA1 or BRCA2 mutations in their tumor. To select patients who may benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d6a4636858a82c5e90e5385671f4c59
https://cris.maastrichtuniversity.nl/en/publications/3fbdaaf0-2158-4279-9942-17585eb83be5
https://cris.maastrichtuniversity.nl/en/publications/3fbdaaf0-2158-4279-9942-17585eb83be5
Autor:
Aisha S. Sie, M.A. Ten Voorde, Ritse M. Mann, H. Kroeze, A. van Erkelens, A. Visser, Nicoline Hoogerbrugge, Judith B. Prins, L.E.M. Duijm, Peggy Manders
Publikováno v:
European Journal of Cancer, 78, pp. 45-52
European Journal of Cancer, 78, 45-52
European Journal of Cancer, 78, 45-52
Item does not contain fulltext INTRODUCTION: Identifying high familial breast cancer (FBC) risk improves detection of yet unknown BRCA1/2-mutation carriers, for whom BC risk is both highly likely and potentially preventable. We assessed whether a new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882fc9f58546ab573b595c9d120e3d00
https://doi.org/10.1016/j.ejca.2017.03.014
https://doi.org/10.1016/j.ejca.2017.03.014
Autor:
Nicoline Hoogerbrugge, Ilse Feenstra, Aisha S. Sie, W. A. G. van Zelst-Stams, Judith B. Prins, Joris A. Veltman
Publikováno v:
Clinical Genetics. 87:319-326
The Radboud University Medical Center was among the first to implement two-step exome sequencing in clinical genetic diagnostics. This study is the first to evaluate patient experiences with gene panels based on exome sequencing, using quantified psy
Publikováno v:
Familial Cancer, 12, 675-82
Familial Cancer, 12, 4, pp. 675-82
Familial Cancer, 12, 4, pp. 675-82
Item does not contain fulltext DNA-testing for BRCA1/2 or Lynch syndrome is possible from the age of 18 years, although surveillance usually starts at 25. Some patients regret their decision of testing before age 25. This retrospective study evaluate
Autor:
Harry Hollema, Henriette J. G. Arts, Aisha S. Sie, Jan C. Oosterwijk, Geertruida H. de Bock, Marian J.E. Mourits, Catheleine van Driel
Publikováno v:
Maturitas, 80(3), 318-322. ELSEVIER IRELAND LTD
Objective: Ovarian cancer screening (OCS) for BRCA1/2 mutation carriers was stopped in our family cancer clinic in 2009 because of its ineffectiveness. The study objective was to investigate the effect of stopping OCS on the timing and uptake of risk
Autor:
Arjen R. Mensenkamp, M.J.L. Ligtenberg, Aisha S. Sie, Eddy M. M. Adang, Nicoline Hoogerbrugge
Publikováno v:
Annals of Oncology, 25, 2001-7
Annals of Oncology, 25, 10, pp. 2001-7
ResearcherID
Annals of Oncology, 25, 10, pp. 2001-7
ResearcherID
Item does not contain fulltext BACKGROUND: Recognising colorectal cancer (CRC) patients with Lynch syndrome (LS) can increase life expectancy of these patients and their close relatives. To improve identification of this under-diagnosed disease, expe
Autor:
Aisha S. Sie, Judith B. Prins, Wendy A. G. van Zelst-Stams, Han G. Brunner, Marjolijn J L Ligtenberg, Arjen R. Mensenkamp, Nicoline Hoogerbrugge, Liesbeth Spruijt
Publikováno v:
BMC Women's Health, 12, pp. 12-12
BMC Women's Health
BMC Women's Health, 12, 12-12
BMC Women's Health, Vol 12, Iss 1, p 12 (2012)
BMC Women's Health
BMC Women's Health, 12, 12-12
BMC Women's Health, Vol 12, Iss 1, p 12 (2012)
Background Current practice for patients with breast cancer referred for genetic counseling, includes face-to-face consultations with a genetic counselor prior to and following DNA-testing. This is based on guidelines regarding Huntington’s disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61a632a01e6ee81e3160cde0ea08d3dc
https://hdl.handle.net/2066/110772
https://hdl.handle.net/2066/110772